#None #Class Action #Faruqi & Faruqi #Novo Nordisk

Overview

Faruqi & Faruqi LLP, a prominent securities law firm, has reiterated a critical message aimed at investors of Novo Nordisk A/S, more commonly known as Novo. The firm is currently investigating potential claims in light of a pending class-action lawsuit, which has a significant deadline approaching on September 30, 2025. This lawsuit could profoundly impact investors who may have suffered losses during a specified period.

The Impending Deadline

As noted, the deadline to apply for the position of lead plaintiff in this class action is September 30, 2025. Investors who believe they have incurred losses exceeding $100,000 while holding Novo shares between May 7, 2025, and July 28, 2025, are encouraged to contact Faruqi & Faruqi for further consultation on their legal options. The firm emphasizes that participation in this lawsuit could be crucial for those affected by the alleged misrepresentation of Novo's business prospects.

Background of the Allegations

The class-action complaint alleges that Novo and its executives made misleading statements and failed to adequately disclose the realities regarding the company's growth potential. Specifically, the lawsuit points out that Novo overlooked the impact of a personalization exception regarding compounded GLP-1s and overestimated the likelihood of patients opting for Novo's branded medications, thereby misrepresenting the market they could potentially capture.

On July 29, 2025, Novo issued a troubling announcement that they were reducing their sales and profit outlook. This significant pivot was attributed to diminished growth expectations for key products such as Wegovy and Ozempic, which were expected to face increased competition and a slower expansion in the market. Following this announcement, Novo’s stock underwent a drastic decline, dropping by approximately 21.83% in a single day—a vivid indication of the market's reaction to the news.

Investor Participation

The court will appoint a lead plaintiff who has the most substantial financial interest among the class members and can adequately represent the concerns of other shareholders. Investors wishing to take a proactive role can file a motion to become the lead plaintiff or may opt to remain part of the class without taking an active role.

However, Faruqi & Faruqi has made it clear that any decision regarding participation as a lead plaintiff will not affect an individual's ability to benefit from any potential recovery. Investors are also welcomed to provide additional information regarding Novo’s operations or past conduct, including first-hand accounts from former employees or anyone else with relevant insights.

Contact Information

For more information about the class-action lawsuit against Novo Nordisk, potential plaintiffs can visit Faruqi & Faruqi’s dedicated webpage at www.faruqilaw.com/NVO or reach out directly to partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310). The firm is known for its successful track record, having recovered significant amounts for investors since its establishment in 1995, and remains committed to all parties involved.

In a time when market conditions are increasingly unpredictable, understanding your rights as an investor is more important than ever. The potential for recovery in securities law suits can provide much-needed recourse for those who feel wronged, ensuring that investors maintain their acquired legal protections.

Conclusion

As the deadline nears for this class action lawsuit against Novo Nordisk, investors are urged to stay informed and take action if they find that they’ve suffered losses within the specified period. With the expertise of Faruqi & Faruqi, there remains a pathway for potentially achieving justice and financial recovery amid market uncertainty. Keep an eye on further announcements from the firm as this vital date approaches. Act quickly to secure your financial interests!